"Genentech thrives on cutting edge science and innovations to advance drug discovery research. It offers me intellectual challenge, curious excitement, and an opportunity to be of service to patients in an effectively scientific environment."
I finished my Ph.D. in immunology at the University of Toronto and joined Fred Alt’s group at Harvard University to complete my postdoctoral research. I joined the Immunology Discovery group at Genentech in the summer of 2007, thus fulfilling my passion for drug discovery research. I am certainly proud of this decision, as I have been able to extend and diversify my expertise in various autoimmune and inflammatory disease areas, allowing me to gain in-depth knowledge about relevant cellular and molecular pathways.
The postdoctoral program at Genentech offers a great opportunity to profoundly advance a scientific area especially in the context of human disease. A collaborative environment, exposure to the best scientific seminars on a regular basis and a tremendous support from various functions enables rapid progress which is hard to match elsewhere.
Sci Signal. 2017 Apr 18;10(475).
Science Signaling, 2015, 8(405), 1-12.
I am leading a core research group in immunology in identifying therapeutic pathways and targets in autoimmune and inflammatory diseases. We utilize almost every possible research tool including animal models, human genetics and tissue samples, biochemistry, structural biology as well elegant drug modalities such as small or large molecules to interrogate pathogenic pathways. My publications reflect on some of the research themes and scientific questions we would like to address including: